Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å teste om BI 771716 hjelper mennesker med en avansert form for aldersrelatert makuladegenerasjon (AMD) kalt geografisk atrofi (VERDANT)

11. november 2026 oppdatert av: Boehringer Ingelheim

Randomisert, dobbeltmasket, AKTIVT KONTROLLERT, multisenterstudie for å evaluere effektiviteten og sikkerheten til to regimer av Intravitreal BI 771716 mot Pegcetacoplan hos deltakere med geografisk atrofi sekundært til aldersrelatert makuladegenerasjon VERDANT-forsøk

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy.

In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye.

Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

202

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Arizona
      • Gilbert, Arizona, Forente stater, 85297
        • Associated Retina Consultants
      • Phoenix, Arizona, Forente stater, 85020
        • Associated Retina Consultants, Ltd.
      • Phoenix, Arizona, Forente stater, 85050
        • Phoenix Retina Associates
      • Scottsdale, Arizona, Forente stater, 85255
        • Retina Macula Institute of Arizona
    • California
      • Glendale, California, Forente stater, 91204
        • Global Research Management
      • Huntington Beach, California, Forente stater, 92647
        • Retina Associates of Southern California
      • Modesto, California, Forente stater, 95356
        • Retinal Consultants Medical Group, Inc
      • Newport Beach, California, Forente stater, 92663
        • Eye Research Foundation
      • Poway, California, Forente stater, 92064
        • Retina Consultants of San Diego
      • Sacramento, California, Forente stater, 95825
        • Retinal Consultants Medical Group
      • Walnut Creek, California, Forente stater, 94598
        • Bay Area Retina Associates - Walnut Creek
    • Colorado
      • Lakewood, Colorado, Forente stater, 80228
        • Colorado Retina Associates
    • Connecticut
      • Danbury, Connecticut, Forente stater, 06810
        • Connecticut Eye Consultants, PC
      • Waterford, Connecticut, Forente stater, 06385
        • Retina Group of New England, PC
    • Florida
      • Deerfield Beach, Florida, Forente stater, 33064
        • Rand Eye Institute
      • Fort Lauderdale, Florida, Forente stater, 33308
        • Retina Group of Florida
      • Pinellas Park, Florida, Forente stater, 33782
        • Eye Associates of Pinellas
      • St. Petersburg, Florida, Forente stater, 33711
        • Retina Vitreous Associates of Florida
    • Georgia
      • Augusta, Georgia, Forente stater, 30909
        • Southeast Retina Center, PC
    • Illinois
      • Lemont, Illinois, Forente stater, 60439
        • University Retina and Macula Associates
      • Oak Park, Illinois, Forente stater, 60304
        • Illinois Retina Associates - Oak Park
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40206
        • Butchertown Clinical Trials
    • Maryland
      • Hagerstown, Maryland, Forente stater, 21740
        • Mid Atlantic Retina Specialists
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Ophthalmic Consultants of Boston
    • Minnesota
      • Edina, Minnesota, Forente stater, 55435
        • Retina Consultants of Minnesota
    • Mississippi
      • Madison, Mississippi, Forente stater, 39110
        • Mississippi Retina Associates
    • Missouri
      • Columbia, Missouri, Forente stater, 65212
        • University of Missouri Health System
    • New Jersey
      • Bloomfield, New Jersey, Forente stater, 07003
        • Envision Ocular, LLC
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87109
        • Eye Associates of New Mexico
    • New York
      • Westbury, New York, Forente stater, 11590
        • Long Island Vitreoretinal Consultants - Westbury
    • Oregon
      • Eugene, Oregon, Forente stater, 97401
        • Verum Research, LLC
    • Pennsylvania
      • Bethlehem, Pennsylvania, Forente stater, 18017
        • Mid Atlantic Retina - Bethlehem
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29414
        • Charleston Neuroscience Institute - Charleston
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Tennessee Retina
    • Texas
      • Austin, Texas, Forente stater, 78750
        • Austin Clinical Research, LLC
      • Beaumont, Texas, Forente stater, 77707
        • Retina Consultants of Texas - Beaumont
      • Bellaire, Texas, Forente stater, 77401
        • Retina Consultants of Texas-Bellaire-67493
      • Dallas, Texas, Forente stater, 75231
        • Retina Foundation of the Southwest
      • Katy, Texas, Forente stater, 77494
        • Retina Consultants of Texas - Katy
      • Plano, Texas, Forente stater, 75024
        • Red River Research Partners, LLC
      • San Antonio, Texas, Forente stater, 78240
        • Retinal Consultants of San Antonio
      • Schertz, Texas, Forente stater, 78154
        • Retina Consultants of Texas - Schertz
      • The Woodlands, Texas, Forente stater, 77384
        • Retina Consultants of Texas-The Woodlands-67575
    • Utah
      • Salt Lake City, Utah, Forente stater, 84107
        • Retina Associates of Utah
    • Virginia
      • Lynchburg, Virginia, Forente stater, 24502
        • Piedmont Eye Center
    • Washington
      • Spokane, Washington, Forente stater, 99204
        • Spokane Eye Clinic

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

50 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion criteria

  • Age at least 50 years old at the time of randomization visit

  • Signed and dated written informed consent in accordance with International Council on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial

  • Male or female participants. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of use are provided in the participant information. Male participants must be ready and able to use either a condom or abstinence as contraceptive measures

  • Diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), where the total GA lesion area must be ≥2.5 square millimetres (mm²) and ≤17.5 mm² as measured by Fundus autofluorescence (FAF)

    • If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥1.25 mm²
    • Note: Fellow eye is not required to have GA
    • Note: subfoveal GA lesions (defined as GA lesions within 1 micron of the foveal center point) will be allowed to be enrolled until a maximum of approximately 60% of participants with subfoveal GA lesions are enrolled. Participants with subfoveal GA lesions already in screening at the time the cap has been reached may be considered for randomization.
  • Fellow eye must have sufficient visual function compared to the study eye, per the investigator's medical judgment in consultation with the patient, to support the patient's daily functioning

  • BCVA letter score of ≥24 letters, using the ETDRS chart in the study eye (equivalent to ≥20/320 on the Snellen chart). Note: If both eyes meet eligibility criteria, the eye with the worse visual function per the investigator's medical judgment in consultation with the patient, will be selected as the study eye. If both eyes have similar visual function, the study eye will be selected per the investigator's medical judgment in consultation with the patient

  • further inclusion criteria apply

Exclusion criteria

  • GA lesions whose area cannot be accurately defined in the study eye

  • Exudative neovascular AMD (eAMD) in the study eye

    -- Note: eAMD in the fellow eye is allowed. However, if the fellow eye is to be considered for microperimetry and other analyses (as defined in the trial statistical analysis plan), then eAMD is not allowed in either eye.

  • Previously received treatment in the study eye for GA secondary to AMD within 4 months or 5 half-lives prior to baseline, whichever is longer

  • Previously received an investigational medication (oral or intravitreal) for GA secondary to AMD within 4 months or 5 half-lives prior to baseline, whichever is longer

  • Currently enrolled in another investigational device or drug trial, or 30 days or 5 half-lives, whichever is longer since ending another investigational device or drug trial(s) or receiving other investigational treatment(s). Any previous use of gene therapy or cell therapy is not permitted

  • Additional eye disease as follows:

    • Any eye disease in the study eye that could compromise BCVA
    • Uncontrolled glaucoma or ocular hypertension with intraocular pressure >24 millimetre of mercury (mmHg) in study eye
    • History of high myopia >8 diopters in the study eye
    • Anterior segment and vitreous abnormalities that would preclude adequate observation with spectral domain optical coherence tomography in the study eye
    • Ocular conditions at the discretion of the investigator that might interfere with outcome of the trial in the study eye
    • Active intraocular inflammation in the study eye
    • Active infectious conjunctivitis in either eye
  • Prior vitrectomy surgery in the study eye

  • History of major intraocular surgeries including major corneal surgery. Uneventful cataract surgery, refractive surgery, oculoplastic surgery, strabismus surgery, and other extraocular surgery may be permitted if they have occurred more than 3 months prior to baseline in the study eye

  • further exclusion criteria apply

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm A: BI 771716

BI 771716

Eksperimentell: Arm B: BI 771716 og Sham komparator

BI 771716

Sham comparator to BI 771716

Aktiv komparator: Arm C: Pegcetacoplan

Pegcetacoplan

Andre navn:
  • Syfovre ®

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Helning av endring fra baseline i kvadratrot transformert geografisk atrofi (GA) område målt ved fundus autofluorescens (FAF) i studieøyet uttrykt i millimeter (mm)/år
Tidsramme: Ved baseline , ved uke 56
Ved baseline , ved uke 56

Sekundære resultatmål

Resultatmål
Tidsramme
Endring fra baseline i kvadratrottransformert GA-areal målt ved FAF i studieøyet uttrykt i mm
Tidsramme: Ved baseline, ved uke 56
Ved baseline, ved uke 56
Endring fra baseline i best korrigert synsskarphet (BCVA) som målt ved standardiserte diabetiske retinopatistudier (ETDRS) i et tidlig forsøk i studieøyet
Tidsramme: Ved baseline, ved uke 56
Ved baseline, ved uke 56
Forekomst av BCVA-brevtap på ≥15 bokstaver målt ved standardisert ETDRS-diagram i studieøyet i minst 2 påfølgende besøk
Tidsramme: Frem til uke 56
Frem til uke 56
Forekomst av eksudativ neovaskulær aldersrelatert makuladegenerasjon (eAMD) i studieøyet fra første legemiddeladministrasjon til uke 56
Tidsramme: Frem til uke 56
Frem til uke 56
Forekomst av legemiddelrelaterte bivirkninger (AE) fra første legemiddeladministrasjon til uke 56
Tidsramme: Frem til uke 56
Frem til uke 56

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. januar 2025

Primær fullføring (Faktiske)

26. oktober 2026

Studiet fullført (Faktiske)

26. oktober 2026

Datoer for studieregistrering

Først innsendt

5. desember 2024

Først innsendt som oppfylte QC-kriteriene

5. desember 2024

Først lagt ut (Faktiske)

9. desember 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 1497-0002
  • U1111-1308-7923 (Registeridentifikator: WHO International Clinical Trials Registry Platform (ICTRP))

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

IPD-delingstidsramme

One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Tilgangskriterier for IPD-deling

For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere